FDA Clears KHN921 Gene Therapy Trial for MYBPC3-Associated Hypertrophic Cardiomyopathy
核心洞察
The US FDA (搜索) granted "study may proceed" clearance for KHN921 (搜索), an AAV9-based gene therapy targeting MYBPC3 (搜索) mutations in hypertrophic cardiomyopathy (搜索) patients.
KHN921 (搜索) delivers a functional copy of the MYBPC3 (搜索) gene via single intracoronary administration, potentially addressing the root genetic cause of this life-threatening condition.
The upcoming Phase I/II trial will evaluate safety, tolerability and efficacy in adults with symptomatic MYBPC3 (搜索) mutation-associated HCM (搜索).
Chengdu Origen Biotechnology (搜索) and Vanotech (搜索) announced that the US FDA (搜索) has granted "study may proceed" clearance for their KHN921 (搜索) Investigational New Drug (IND) application, marking a significant milestone for gene therapy development in hypertrophic cardiomyopathy (搜索) (HCM (搜索)). The therapy targets patients with HCM associated with MYBPC3 (搜索) mutations, representing a novel approach to address the underlying genetic cause of this life-threatening cardiovascular disorder.
Novel Gene Therapy Approach
KHN921 (搜索) is a recombinant replication-deficient adeno-associated virus vector of serotype AAV9 that encodes the MYBPC3 (搜索) protein. The therapy is designed to deliver a functional copy of the MYBPC3 gene directly to cardiomyocytes, potentially restoring normal myosin-binding protein C (搜索) expression and addressing the root cause of the disease.
"KHN921 (搜索) is an AAV-based gene therapy designed to directly address the root genetic cause of HCM (搜索) by delivering a functional copy of the MYBPC3 (搜索) gene and restoring normal myosin-binding protein C (搜索) expression in cardiomyocytes," said Avner Ingerman, M.D., Chief Medical Officer of Vanotech (搜索). "With the FDA's IND clearance, we are one step closer to bringing this potentially transformative therapy to patients who currently face limited long-term treatment options for this life-threatening disease."
Promising Preclinical Results
In preclinical studies using HCM (搜索) disease models, intracoronary infusion of KHN921 (搜索) demonstrated encouraging results. The treatment resulted in retention of the transgene product in cardiac tissues for prolonged periods and prevented disease symptoms. These findings suggest the potential for KHN921 to offer a single administration treatment for HCM patients with MYBPC3 (搜索) mutations.
Clinical Trial Design
The proposed multi-center, open-label, dose escalation and expansion Phase I/II study will assess the safety, tolerability and efficacy of a single intracoronary administration of KHN921 (搜索) gene therapy in adults with symptomatic MYBPC3 (搜索) mutation-associated HCM (搜索). This trial design reflects the therapy's potential for single-dose treatment, which could represent a significant advancement over current management approaches.
Addressing Significant Unmet Medical Need
Hypertrophic cardiomyopathy (搜索) is the most common monogenic cardiovascular disorder, affecting approximately 1 in 500 individuals worldwide. The condition is characterized by unexplained left ventricular hypertrophy, which can lead to heart failure (搜索), arrhythmias (搜索), and sudden cardiac death (搜索), particularly in young adults and athletes.
Mutations in the MYBPC3 (搜索) gene, which encodes cardiac myosin-binding protein C (搜索) (cMyBP-C (搜索)), are one of the most prevalent genetic causes of HCM (搜索). This protein serves as a key regulator of sarcomere structure and cardiac contraction. Pathogenic MYBPC3 mutations lead to impaired or truncated protein production, disrupting normal cardiac function and driving the pathological remodeling characteristic of HCM.
Currently, no disease-modifying therapies targeting the underlying genetic cause of MYBPC3 (搜索)-associated HCM (搜索) have been approved, representing a significant unmet medical need in cardiovascular medicine.
Company Background
Chengdu Origen is a clinical-stage gene therapy company focused on developing gene therapy for unmet medical needs and providing meaningful clinical benefits for patients suffering from genetic and chronic diseases. The company maintains comprehensive viral vector manufacturing capabilities and infrastructure.
Vanotech (搜索) operates as the sponsor-representative and is responsible for the clinical development program of KHN921 (搜索) in the United States. The company is also currently conducting additional gene therapy trials, including VAN-2201 and VAN-2401, both Phase I studies evaluating gene therapies for neovascular age-related macular degeneration.